Hostname: page-component-745bb68f8f-d8cs5 Total loading time: 0 Render date: 2025-02-12T06:09:36.974Z Has data issue: false hasContentIssue false
  • English
  • Français

New Directions in the Pharmacologic Treatment of Insomnia

Published online by Cambridge University Press:  07 November 2014

David Neubauer
Get access Rights & Permissions [Opens in a new window]

Extract

Because a multitude of factors contribute to insomnia, the context of treatment can greatly impact treatment efficacy. Major depression or congestive heart failure, for example, can contribute to insomnia, and treatment of those conditions should exert a positive effect on insomnia symptoms. On the other hand, the treatment of other conditions, such as the use of selective serotonin reuptake inhibitors antidepressants, may have a negative effect on the quality of sleep. Clinicians, therefore, need to take a versatile, multifaceted approach for each patient when treating insomnia.

Type
Expert Panel Supplement
Information
CNS Spectrums , Volume 13 , Issue S17: New Perspectives in the Diagnosis and Management of Insomnia , December 2008 , pp. 10 - 12
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Morin, CM, Bootzin, RR, Buysse, DJ, Edinger, JD, Espie, CA, Lichstein, KL. Psychological and behavioral treatment of insomnia: Update of the recent evidence (1998–2004). Sleep. 2006;29:1398–1414.CrossRefGoogle ScholarPubMed
2.Ramakrishnan, K, Scheid, DC. Treatment options for insomnia. Am Fam Physician. 2007;76(4):517–526.Google ScholarPubMed
3.Mignot, E, Taheri, S, Nishino, S. Sleeping with the hypothalamus: emerging therapeutic targets for sleep disorders. Nat Neurosci. 2002;5(suppl):1071–1075.CrossRefGoogle ScholarPubMed
4.Möhler, H, Fritschy, JM, Rudolph, U. A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002;300(1):2–8. Review.CrossRefGoogle ScholarPubMed
5.Rowlett, JK, Cook, JM, Duke, AN, Platt, DM. Selective antagonism of GABAA receptor subtypes: an in vivo approach to exploring the therapeutic and side effects of benzodiazepine-type drugs. CNS Spectr. 2005;10(1):40–48.CrossRefGoogle Scholar
6.Walsh, JK, Roehrs, T, Roth, T. Pharmacologic treatment of primary insomnia. In: Kryger, MH, Roth, T, Dement, WC, eds. Principles and Practice of Sleep Medicine. 4th ed.Philadelphia, PA: Elsevier Inc.; 2005:749–760.CrossRefGoogle Scholar